Active substance
Results for the substance umeclidinium+vilanterol
1 result
About this active substance
Umeclidinium + vilanterol is a combination medication used for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This combination contains umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta-2 adrenergic agonist (LABA).
Umeclidinium works by relaxing the smooth muscles in the airways, reducing bronchoconstriction, while vilanterol improves airflow by stimulating beta-2 adrenergic receptors. Together, these medications help alleviate symptoms such as shortness of breath and coughing, improving the quality of life for patients with COPD.
The medication is administered via inhaler, once daily, as directed by a physician. Common side effects include headache, throat irritation, and upper respiratory tract infections. In rare cases, allergic reactions or worsening respiratory symptoms may occur.
Umeclidinium + vilanterol is an effective therapeutic option for long-term management of COPD, helping to reduce exacerbations and improve lung function.
Umeclidinium works by relaxing the smooth muscles in the airways, reducing bronchoconstriction, while vilanterol improves airflow by stimulating beta-2 adrenergic receptors. Together, these medications help alleviate symptoms such as shortness of breath and coughing, improving the quality of life for patients with COPD.
The medication is administered via inhaler, once daily, as directed by a physician. Common side effects include headache, throat irritation, and upper respiratory tract infections. In rare cases, allergic reactions or worsening respiratory symptoms may occur.
Umeclidinium + vilanterol is an effective therapeutic option for long-term management of COPD, helping to reduce exacerbations and improve lung function.